Results 121 to 130 of about 3,942,933 (245)

Engineering‐Modulated Molybdenum Enzymes Strategy for Tumor‐Specific Metabolic‐Immunotherapy

open access: yesAdvanced Science, EarlyView.
Biodegradable molybdenum sulfide nanoparticles were synthesized via a one‐pot strategy to increase molybdenum enzyme activity and thus effectively potentiate anti‐tumor immunity by integrating molybdenum‐based metalloimmunotherapy with hydrogen sulfide gas therapy.
Xiaoxiao Pan   +14 more
wiley   +1 more source

Engineering a 660 nm‐Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy

open access: yesAdvanced Science, EarlyView.
This study reports a bioorthogonal pyroptosis inducer, PyroRACS. By using a red‐light‐responsive Cre‐On genetic switch to control the expression of highly cytotoxic GSDMDNT, PyroRACS enables the artificial induction of pyroptosis with precise spatiotemporal control.
Mengkai Zhang   +5 more
wiley   +1 more source

Machine‐learning‐based integration of tumor microenvironment features predicting immunotherapy response

open access: yesMedComm – Future Medicine
Immunotherapy has revolutionized cancer treatment in recent years, yet non‐responsiveness of immunotherapy remains a challenge for cancer treatment.
Kunpeng Luo   +6 more
doaj   +1 more source

Computation and Structure‐Guided Arginine Scanning Engineers a Hyperactive AP Endonuclease for Multiplex Viral RNA Sensing

open access: yesAdvanced Science, EarlyView.
Computational and structure‐guided arginine scanning rewires the DNA‐binding interface of APE1 to create APE1‐Evo, a hyperactive yet specific AP endonuclease. Integrated into the NAPTUNE‐V2.0 cascade, APE1‐Evo enables amplification‐free, multiplex viral RNA sensing for dengue virus and influenza A/B, highlighting a general strategy for engineering ...
Junlan Wang   +20 more
wiley   +1 more source

Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade

open access: yesCancer Communications
Background Immune checkpoint blockade (ICB) has revolutionized the treatment of various cancer types. Despite significant preclinical advancements in understanding mechanisms, identifying the molecular basis and predictive biomarkers for clinical ICB ...
Jie Mei   +19 more
doaj   +1 more source

Genetic Ablation and Multi‐Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models

open access: yesAdvanced Science, EarlyView.
Genetic ablation of Cep55 in Pten‐deficient mouse models delays tumorigenesis. Integrated multi‐omics analyses (proteomics, phosphoproteomics, and spatial transcriptomics) reveal that CEP55 regulates oncogenic signaling (RAS/ERK, PI3K/AKT), integrin/FAK‐mediated adhesion, extracellular matrix (ECM) remodeling, and endocytosis.
Behnam Rashidieh   +22 more
wiley   +1 more source

Next‐generation sequencing identifies that protein tyrosine phosphatase receptor type D mutation is favorable to immunotherapy in human cancer

open access: yesMedComm – Oncology
Protein tyrosine phosphatase receptors (PTPRs) play a crucial part in numerous tumor processes. However, the effect of PTPR mutations on the immune checkpoint inhibitor (ICI) response needs to be further clarified.
Yongsheng Huang   +16 more
doaj   +1 more source

EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple‐Negative Breast Cancer Progression

open access: yesAdvanced Science, EarlyView.
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong   +10 more
wiley   +1 more source

DRAM1‐defined autophagy‐JAK‐STAT‐Tregs axis drives immunosuppression and predicts immunotherapy response in pan‐cancer

open access: yesClinical and Translational Discovery
Background DNA damage‐regulated autophagy modulator 1 (DRAM1) is a lysosomal protein involved in autophagy regulation, yet its comprehensive role across human cancers, particularly within the TIME, remains systematically uncharacterized.
Jinchun Wu   +7 more
doaj   +1 more source

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

open access: yesAdvanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy